Savara Inc. (NASDAQ:SVRA) is anticipated to reveal earnings on March, 13., according to RTT. earnings per share of $-0.37 is 60.87 % down from 2018’s $-0.23 EPS. Wall Street predicts 0.00 % EPS growth as of March, 13. SVRA is touching $7.4 during the last trading session, after decreased 9.09%.Savara Inc. is downtrending after having declined 31.49% since March 7, 2018. SVRA has 255,113 volume or 48.63% up from normal. SVRA underperformed the S&P 500 by 35.86%.

Savara Inc., a clinical-stage specialty pharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases.The firm is worth $259.95 million. The Company’s product pipeline comprises AeroVanc, a Phase III ready inhaled formulation of vancomycin for the treatment of persistent methicillin-resistant staphylococcus aureus and lung infection in cystic fibrosis patients; Molgradex, a Phase II/III stage inhaled granulocyte-macrophage colony-stimulating factor for the treatment of autoimmune pulmonary alveolar proteinosis; and Aironite, an inhaled nebulized sodium nitrite solution to treat heart failure with preserved ejection fraction.Last it reported negative earnings.

For more Savara Inc. (NASDAQ:SVRA) news released recently go to: Globenewswire.com, Globenewswire.com, Nasdaq.com, Globenewswire.com or Globenewswire.com. The titles are as follows: “Savara Provides Update on IMPALA and AVAIL Pivotal Clinical Studies – GlobeNewswire” released on February 06, 2019, “Savara Announces Pricing of Public Offering of Common Stock – GlobeNewswire” on July 26, 2018, “Notable Wednesday Option Activity: AVLR, LRN, SVRA – Nasdaq” with a publish date: January 23, 2019, “Savara Reports Third Quarter 2018 Financial Results and Provides Business Update – GlobeNewswire” and the last “Savara Becomes Inaugural Foundation Sponsor of the PAP Foundation – GlobeNewswire” with publication date: August 27, 2018.